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In the past decades, a persistent progression of diabetic vascular complications despite reversal of hyperglycemia has been ob-
served in both experimental and clinical studies. This durable effect of prior hyperglycemia on the initiation and progression of 
diabetic vasculopathies was defined as “metabolic memory”. Subsequently, enhanced glycation of cellular proteins and lipids, 
sustained oxidative stress, and prolonged inflammation were demonstrated to mediate this phenomenon. Recently, emerging 
evidence strongly suggests that epigenetic modifications may account for the molecular and phenotypic changes associated 
with hyperglycemic memory. In this review, we presented an overview on the discovery of metabolic memory, the recent pro-
gress in its molecular mechanisms, and the future implications related to its fundamental research and clinical application. 
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1  The discovery of metabolic memory 
Diabetes mellitus is one of the most common chronic dis-
eases in the world today. It was estimated that approxi-
mately 285 million adults (aged 2079 years) were suffer-
ing from diabetes around the globe in 2010, and this number 
may rapidly increase to 439 million by 2030 [1]. In this re-
gard, reducing the burden of diabetes remains to be a major 
challenge for both clinical doctors and bench scientists. 
Although the advent of insulin therapy in 1922 prolonged 
life expectancy in diabetes patients, micro- and macrovas-
cular complications have gradually become the most serious 
manifestations in patients with long-standing diabetes [2]. 
Microvascular complications are disabling and more diabe-
tes-specific, whereas macrovascular complications are 
life-threatening and primarily caused by accelerated athero-
sclerosis. The devastating consequences of the long-term 
complications led to a series of intensive studies and vigor-
ous debates over their pathoetiology. Although the underly-
ing mechanisms seemed to differ between micro- and 
macrovasculopathies, hyperglycemia was generally pro-
posed as the culprit in the last century. This is also known 
as the “glucose hypothesis” [3].  
To test this hypothesis, Diabetes Control and Complica-
tions Trial (DCCT) was designed and conducted from 1982 
to 1993. It was a controlled clinical trial in 1441 subjects 
(aged 1339 years) with recently diagnosed type 1 diabetes 
mellitus (T1DM), comparing intensive insulin therapy (INT) 
with conventional insulin therapy (CNT). While INT aimed 
at achieving glucose levels as close to the nondiabetic range 
as safely possible, CNT aimed to maintain safe asympto-
matic glucose control. In DCCT, the median HbA1c level 
was 7% in INT compared with 9% in CNT. At study end, 
improved glycemic control was associated with a lower 
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incidence and progression of retinopathy, nephropathy, and 
neuropathy, suggesting that early and intensive insulin 
therapy was beneficial for ameliorating diabetic microvas-
cular complications [4]. 
In light of the successful completion of the DCCT, an 
observational follow-up study of the DCCT cohort, the Ep-
idemiology of Diabetic Interventions and Complications 
(EDIC) study, was initiated to investigate the long-term 
effects of the original DCCT INT on the development of 
microvascular complications, as well as on the incidence of 
macrovascular complications that were not observed in 
DCCT due to its relatively short duration. During EDIC, 
more beneficial intensive regime was advised to CNT group 
as the new standard of care, resulting in a narrowing and 
then disappearance of the differences in HbA1c maintained 
during DCCT [3]. Surprisingly, despite the loss of separa-
tion in HbA1c as early as the first year of EDIC, the first 
four years of the EDIC follow-up demonstrated a further 
widening of the difference in microvascular outcomes (ret-
inopathy and nephropathy) [5], and the beneficial effects of 
former DCCT INT on microvascular complications persis-
tently exist even when EDIC enters its third decade [68]. 
In addition, former DCCT INT was also found to be    
associated with macrovascular complications, represented 
by a substantial reduction in the risk of cardiovascular  
diseases [9].  
Similarly, the United Kingdom Prospective Diabetes 
Study (UKPDS), another controlled trial which recruited 
5102 subjects (aged 2565 years) with newly diagnosed 
T2DM from 1977 to 1991 and followed the cohort for about 
10 years, also demonstrated persistent benefits of prior in-
tensive diabetes management on both micro- and macro-
vascular complications [10,11]. During the trial phase, sub-
jects were assigned to receive either conventional dietary 
treatment, aimed at maintaining fasting plasma glucose lev-
el <15 mmol L1 (CNT), or intensive glycemic control with 
insulin or a sulfonylurea, aimed at maintaining a fasting 
plasma glucose level <6 mmol L1 (INT). In the trial phase 
of UKPDS, the median HbA1c level was 7.0% in INT com-
pared with 7.9% in CNT. This difference correlated with a 
25% risk reduction in the development of microvascular 
complications, in spite of insignificant correlation in the 
incidence of macrovascular complications [10]. During the 
following 10-year observational phase, no attempts were 
made to maintain previously assigned therapies and be-
tween-group differences in HbA1c were lost after the first 
year. Despite disappearance of the difference, however, a 
persistent reduction in the incidence of microvascular com-
plications and a significantly lower incidence of macrovas-
cular complications (myocardial infarction and all-cause 
mortality) were observed in INT compared with CNT [11]. 
Since these clinical trials and subsequent epidemiological 
studies with both T1DM and T2DM respectively revealed a 
long-lasting memory-like phenomenon strongly associated 
with prior hyperglycemia, this durable effect of early gly-
cemic control on the initiation and progression of diabetic 
vascular complications were, then, collectively termed as 
the “metabolic memory” phenomenon [3]. 
In fact, long before the above mentioned large-scale 
clinical trials, phenomena resembling metabolic memory 
had already been described in cell culture and animal mod-
els of diabetes as early as in the 1980s. Engerman et al. [12] 
showed that dogs subjected to poor glycemic control (PC) 
for 2.5 years and then treated with insulin to maintain good 
glycemic control (GC) for another 2.5 years still developed 
incipient diabetic retinopathy. In contrast, dogs treated with 
insulin within two months of the development of diabetes 
and maintained GC for subsequent five years exhibited sig-
nificantly lesser signs of retinopathy. Shortly afterward, 
Roy et al. [13] further showed that transient hyperglycemic 
stimulation could persistently increase the expression of 
fibronectin and collagen IV mRNA in cultured human en-
dothelial cells exposed to PC and followed by GC. Consist-
ently, Hammes et al. [14] found that, while islet transplanta-
tion in rats within six weeks of diabetes significantly slowed 
the development of diabetic retinopathy and prevented reti-
nal vessel occlusion, transplantation 12 weeks after the de-
velopment of diabetes only partially slowed the progression 
towards retinopathy and failed to prevent vessel occlusion. 
Although these pioneer work jointly implied a novel con-
cept of hyperglycemic memory, not enough attention was 
given to these basic scientific researches until their clinical 
relevance was established in large-scale trials, such as 
DCCT/EDIC and UKPDS, in the early 21st century. 
During the investigation of EDIC, mechanistic studies 
have already been performed in DCCT/EDIC cohorts 
[1517]. For instance, Genuth et al. [15] reported that the 
earlier measurements of glycated collagen and advanced 
glycation end product (AGE) levels strongly correlated with 
the risk of progression of retinopathy and nephropathy from 
the end of the DCCT to 10 years later. In addition, glycated 
collagen, rather than AGEs, explained more of the variation 
in the 10-year progression of these complications. Further-
more, the predictive effect of HbA1C disappeared after ad-
justment for glycated collagen and AGEs. Hence, these re-
sults collectively indicated that glycation and subsequent 
AGE formation may be the driving force for the persistent 
progression of diabetic microvascular complications [15]. 
Ever since, metabolic memory and its underlying mecha-
nisms have attracted broad interest. 
2  The mechanisms of metabolic memory 
2.1  Oxidative stress plays central roles in the occur-
rence of metabolic memory 
Previously, five major mechanisms have been demonstrated 
to mediate hyperglycemia-induced tissue damage: (i) in-
creased flux of glucose through the polyol pathway; (ii) 
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increased intracellular formation of AGEs (advanced gly-
cation end products); (iii) increased expression of the re-
ceptor for AGEs and its activating ligands; (iv) activation of 
protein kinase C (PKC) isoforms; and (5) overactivity of the 
hexosamine pathway [18]. Moreover, several lines of evi-
dence have suggested that all of these mechanisms are acti-
vated by a single upstream event: mitochondrial overpro-
duction of reactive oxygen species (ROS) and subsequently 
exacerbated intracellular oxidative stress [19]. Therefore, 
tremendous focus has been laid on the pivotal roles of oxi-
dative stress in the development of metabolic memory. 
In 2007, two research groups respectively demonstrated 
the central roles of persistent oxidative stress in the cellular 
memory of hyperglycemia [20,21]. Ihnat et al. [20] showed 
that, in ARPE-19 retinal cells in culture, as well as in the 
retina of diabetic rats, markers of oxidative stress and mito-
chondrial damage (e.g., PKC-β, NADPH oxidase p47phox, 
PARP, 3-nitrotyrosine, and Bax) remained upregulated for 
one week of GC after being exposed for two weeks of PC. 
Surprisingly, while blocking sources of extra-mitochondrial 
ROS production only reduced some of the persistently in-
duced stress markers, overexpression of the mitochondrial 
respiratory chain uncoupling protein UCP2 or α-lipoic acid 
during the normalization period reduced the induction of all 
the stress proteins, indicating that persistence of oxidative 
stress, especially mitochondrial ROS overproduction, may 
account for the memory phenomenon.  
Consistently, Kowluru et al. [21] reported that peroxyni-
trite accumulation was significantly increased in rat retinal 
microvasculature in response to six months of PC and failed 
to normalize after six additional months of GC. In the 
meantime, the activity of manganese superoxide dismutase 
(MnSOD), the enzyme responsible for scavenging mito-
chondrial superoxide, remained inhibited in the same rat 
retina and the total antioxidant capacity was subnormal 6 
months after cessation of PC. Successively, Kowluru and 
colleagues performed a series of studies in rat retina with 
similar experimental settings (26 months of PC followed 
by 26 months of GC). It was shown that, not only the 
structure and biogenesis of mitochondria remained persis-
tently impaired in spite of reversal of hyperglycemia 
[2226], but the genes and biomarkers of inflammation and 
apoptosis were also closely associated with metabolic 
memory [27,28]. 
A recent study done by Zheng et al. [29] further extended 
our understanding on oxidative stress-mediated metabolic 
memory in diabetic retinopathy. In bovine retinal capillary 
endothelial cells (BRECs) and the retina of diabetic rats 
treated with two weeks of hyperglycemia and one week of 
normoglycemia, hyperglycemia-induced Bax and NF-κB 
remained elevated after returning to normoglycemia. Small 
interfering RNA-mediated SIRT1 knockdown had increased 
sensitivity to hyperglycemia stress, whereas SIRT1 overex-
pression or activation by metformin inhibited the increase of 
mitochondrial ROS overproduction and ultimately sup-
pressed the expression of Bax and NF-B, via the SIRT1/ 
LKB1/AMPK/ROS/PARP pathway. Furthermore, hyper-
glycemia was found to induce PARP activation, which in 
turn may downregulate SIRT1, implying a potential au-
to-feedback loop amplifying mitochondrial ROS overpro-
duction and exacerbating intracellular oxidative stress.  
2.2  Epigenetic mechanisms contribute to the chronicity 
of metabolic memory 
In the last decade, with a surge in the discovery of epige-
netic modifications induced by variations in glucose levels, 
oxidative stress-mediated metabolic memory was demon-
strated to be mediated by epigenetic mechanisms. Epige-
netic modifications refer to a variety of stable and heritable 
patterns that regulate gene expression without altering the 
DNA sequence. In general, epigenetic modifications consist 
of three types of regulation: (i) transcriptional inhibition by 
hypermethylation of CpG dinucleotides at gene promoters; 
(ii) transcriptional activation or inhibition through acetyla-
tion and/or methylation at histone tails; and (iii) post-  
transcriptional inhibition via microRNAs. As an important 
complement to the classic control of gene expression, epi-
genetic mechanisms modulate a variety of long-lasting en-
vironment-gene interactions during the development of di-
abetes and its vascular complications [30]. 
In the context of diabetic retinopathy, all the three types 
of control have been found to be directly associated with 
metabolic memory [3134]. For instance, in a study per-
formed by Zhong et al. [32], streptozotocin-induced diabetic 
rats were maintained in PC for two months and followed by 
GC for two additional months. It was shown that initial PC 
upregulated trimethyl histone H4 lysine 20 (H4K20me3), 
acetyl histone H3 lysine 9 (H3K9), and NF-κB p65 at the 
promoter and enhancer regions of Sod2, the nuclear gene 
encoding MnSOD, in isolated retinal endothelial cells. Sub-
sequent reversal of hyperglycemia was unable to prevent 
these increases, resulting in decreased expression of 
MnSOD. Moreover, SUV420h2, one of the prime enzymes 
for the trimethylation of H4K20, were found to mediate the 
increased H4K20me3 at Sod2 and thus contribute to the 
occurrence of metabolic memory. In another study of the 
same research group [34], monomethyl H3K4 (H3K4me1), 
dimethyl H3K4 (H3K4me2), and lysine-specific demethyl-
ase-1 (LSD1) were examined at Sod2 in a similar experi-
mental setting (PC for 3 months followed by GC for 3 
months). Initial hyperglycemia reduced H3K4me1 and -me2, 
and increased the binding of LSD1 at Sod2. These changes 
remained unaffected after reinstitution of normoglycemia, 
but were reversed by LSD1-siRNA in rat retinal endothelial 
cells. Retina from human donors with diabetic retinopathy 
also had decreased H3K4me2 and increased LSD1 at Sod2. 
Collectively, since H3K4me1 and H3K4me2 are active 
markers, and H4K20me3 is a repressive epigenetic marker 
of gene transcription, these results imply that the metabolic 
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memory phenomenon of continuously decreased retinal 
MnSOD may be regulated by a complex array of 
post-transcriptional histone modifications. Despite advances 
in diabetic retinopathy, however, we are still at the very 
beginning to understand the underlying mechanisms of 
metabolic memory in other microvascular complications, 
such as diabetic nephropathy [35] and neuropathy [36,37]. 
In parallel with microvascular complications, huge pro-
gress has also been made in oxidative stress-mediated met-
abolic memory on the macrovasculature. In human aortic 
endothelial cells (HAECs) exposed to high glucose and 
aortas of diabetic mice, activation of the mitochondrial 
adaptor p66Shc by PKC-βII persisted after returning to 
normoglycemia (3 d of hyperglycemia followed by 3 d of 
normoglycemia). Persistent p66Shc upregulation and mito-
chondrial translocation were associated with continued ROS 
production, reduced nitric oxide (NO) availability, and 
apoptosis. Moreover, p66Shc activation accounted for the 
persistent elevation of AGEs. Of note, the overexpression of 
p66Shc was found to be epigenetically regulated by promoter 
CpG hypomethylation and general control nonderepressible 
5 (GCN5)-induced acetylation at H3. p66Shc-derived ROS 
production maintained PKC-βII upregulation and PKC-βII- 
dependent inhibitory phosphorylation of endothelial nitric 
oxide synthase (eNOS) at Thr-495, leading to a vicious cy-
cle despite restoration of normoglycemia. More importantly, 
in vivo gene silencing of p66Shc, performed at the time of 
glucose normalization, ameliorated persistent endothelial 
dysfunction and vascular apoptosis [38]. Hence, p66Shc is 
the key effector promoting the acceleration of diabetic 
macrovascular complications, and it may serve as a novel 
therapeutic target to reduce the deleterious effect of meta-
bolic memory.  
In another macrovascular cell model of metabolic 
memory, human umbilical vein endothelial cells (HUVECs) 
were incubated in high glucose for 14 d followed by normal 
glucose for 7 d. The effects of gliclazide and glibenclamide 
were added to the culture media early (first 14 days), late 
(last 7 days), or throughout the study to evaluate markers of 
oxidative stress and apoptosis. It was observed that 
gliclazide applied early or throughout the study partially 
improved endothelial cell apoptosis by reducing oxidative 
stress, while glibenclamide showed no relevant effect, im-
plying that the increase in ROS production may be a prima-
ry, yet reversible biological event following hyperglycemia 
[39]. Accordingly, whether the downstream targets of ROS 
production may also confer metabolic memory on vascular 
cells is attracting growing attention. 
Indeed, El-Osta et al. [40] demonstrated that the in-
creased expression of NF-κB p65 gene after 16 h of hyper-
glycemia was retained for up to 6 d following reinstitution 
of normoglycemia in human microvascular endothelial cells 
(HMEC-1). In addition, a similar trend was also observed in 
the isolated aorta of non-diabetic mice subject to four se-
quential injections of high glucose solution at 2-h intervals. 
The sustained expression of the NF-κB p65 was associated 
with both upregulation of an active marker (H3K4m1) and 
downregulation of repressive markers (H3K9m2 and 
H3K9m3) of gene transcription, as a result of altered re-
cruitment of relevant histone methyltransferases (SET7 and 
SUV39h1) and demethylases (LSD1) to the p65 promoter. 
In a follow-up study, the authors [41] also showed that the 
NF-κB target genes may also subject to sustained epigenetic 
modifications (e.g., SET7-mediated H3K4m1) in response 
to prior hyperglycemia. Based on these findings, it can be 
speculated that transient high glucose insults may simulta-
neously or hierarchically induce persistent epigenetic 
changes on a variety of genes that work in concert with each 
other to maintain the detrimental memory effects of hyper-
glycemia in either micro- or macrovascular endothelial 
cells. 
In addition to endothelial cells, other cell types in 
macrovasculature, such as macrophages and vascular 
smooth muscle cells (VSMCs) were also associated with 
epigenetically-regulated metabolic memory. For example, 
Natarajan and colleagues [42] showed that the expression of 
inflammatory genes, monocyte chemoattractant protein-1 
(MCP-1) and interleukin-6 (IL-6), were increased in 
VSMCs isolated from 911 weeks old male diabetic db/db 
mice, and retained even after up to eight weeks of normo-
glycemic in vitro culture. This memory phenomenon was 
mediated by sustained decreases in H3K4me3 levels and 
SUV39h1 occupancy at their promoters. Furthermore, the 
same research group [43] demonstrated that increased 
miR-125b in response to hyperglycemic stimulation could 
promote the expression of MCP-1 and IL-6 by targeting 
SUV39h1 mRNAs. It remains unclear whether miR-125b 
would sustain after reversal of hyperglycemia and continu-
ously contribute to the occurrence of metabolic memory. 
Nonetheless, this cross-talk regulation between different 
types of epigenetic regulations strongly implies that dy-
namically-changed microRNAs can exert crucial roles in 
fine-tuning the functions of long-lasting epigenetic codes 
(e.g., histone modifications and DNA methylations) and 
thus may synergistically modulate the development of dia-
betic vascular complications.  
Taken together, previous studies have well recognized 
mitochondrial ROS generation as a unifying mechanism for 
the pathogenesis of diabetes and its chronic complications 
[18,19]. Since the discovery of metabolic memory in both 
preclinical [1214] and clinical [39,11] studies, transient 
hyperglycemia-induced persistent ROS overproduction has 
been closely associated with the memory phenomenon in 
both micro- [2029] and macrovascular [38,40] complica-
tions . Recently, stable and heritable epigenetic machinery, 
such as DNA methylations and histone modifications, added 
a new layer of gene regulation, not only to oxidative 
stress-related pathways [3134,38,39] but also inflamma-
tion-associated signalings [4042]. Furthermore, dynami- 
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cally-changed microRNAs have been proposed to coordi-
nate the formation of cellular memory, and thus may con-
tribute to the chronicity of the disease [43]. These novel 
findings extended our understanding about the underlying 
mechanisms of metabolic memory in diabetic vasculopa-
thies. 
3  Clinical perspectives and future implications 
During the last decades, studies have found numerous bi-
omarkers, such as HbA1c [4446], skin collagen glycation 
[15], plantar fascia thickness [47], AGEs [48,49], oxidized 
low-density lipoprotein (oxLDL) [49], nitric oxide meta-
bolic pathway products (NOx) [49], as well as H3K9 acety-
lation in monocyte [17], to predict the progression of dia-
betic vascular complications and the occurrence of meta-
bolic memory. Recently, circulating microRNAs have been 
associated with diabetes and its vascular complications [50]. 
For instance, miR-126, a highly endothelium-enriched mi-
croRNA, has been shown to be packaged into circulating 
microparticles and delivered to neighboring endothelial 
cells to further modulate their cellular functions. Addition-
ally, miR-126 was significantly reduced in endotheli-
um-derived microparticles and endothelial progenitor cells 
from diabetic patients, which, in turn, contributed to the 
initiation of diabetic vasculopathies [51,52]. Although the 
functional roles of circulating microRNAs (e.g., miR-126) 
in metabolic memory are still obscure, with growing under-
standing on their extracellular communication machinery, 
circulating microRNAs may hold a great potential as diag-
nostic markers for monitoring the progression of diabetic 
vascular complications.  
In terms of therapeutics, the discovery of metabolic 
memory strongly supports the adoption of a more aggres-
sive treat-to-target approach, instead of waiting for treat-
ment failure. Although some anti-diabetes drugs (e.g., met-
formin) and antioxidant substances (e.g., MnSOD) have 
been shown to partially reverse metabolic memory at the 
experimental level, whether these chemicals may also bring 
benefits in real clinical practice still warrants thorough in-
vestigation. Interestingly, a latest effort made by Natarajan 
et al. taken the discovery of microRNAs to a higher level in 
the context of diabetic vasculopathies. Previously, miR-192 
has been demonstrated as a master up-stream regulator in 
diabetic nephropathy, because it presides over a cascade of 
events leading to glomerular hypertrophy [53]. By treating 
diabetic mice with a locked nucleic acid (LNA)-modified 
inhibitor of miR-192 (LNA-anti-miR-192) from the onset of 
diabetes up to 17 weeks, Putta et al. [54] found a concomi-
tant decreased gene expression in collagen, TGF-β, and 
fibronectin, and ameliorated renal fibrosis in diabetic 
nephropathy, indicating that LNA-miR-192 may serve as an- 
ideal tool of pharmaceutical intervention against the for-
mation of diabetic vascular complications. However, 
whether LNA-miR-192, as well as other microRNA inhibi-
tors, may actually exert similar effects against the progres-
sion of metabolic memory needs to be answered.  
On the other hand, results from the Outcome Reduction 
With Initial Glargine Intervention (ORIGIN) trial, the first 
large-scale study specifically designed to test the effects of 
early insulin therapy on patients with recent-onset diabetes 
and high cardiovascular risk, showed no benefit over com-
parator therapies (sulfonylureas and metformin), both for 
micro- and macrovascular diabetic complications [55]. 
Meanwhile, the STENO-2 and a more recent observational 
study on the role of blood glucose control have shown the 
crucial roles of controlling lipids, hypertension, and hyper-
coagulability on macrovascular outcomes [5658]. These 
findings may jointly imply that considerable difference may 
exist in the mechanisms of microvascular complications 
developed from T1MD and T2MD, and that although hy-
perglycemia may be directly responsible for microvascular 
complications, other risk factors may also be very crucial 
for macrovascular complications. Therefore, despite the 
benefit of early aggressive glycemic control on preventing 
metabolic memory, challenges remain to find appropriate 
drugs and time points of intervention for each individual 
patient with overt and clinical diabetes. Of importance, 
emerging evidence suggests that micro- and macrovascular 
dysfunctions may interact with each other to further amplify 
the potential impact of metabolic memory [5961]. Thus, 
future studies should also regard both micro- and macro-
vasculopathies as a whole, so as to acquire a more compre-
hensive view on the underlying mechanisms of their patho-
genesis, and to develop more feasible and effective clinical 
strategies against the occurrence and persistence of hyper-
glycemia-induced metabolic memory. 
In summary, the discovery of metabolic memory and 
novel insights into its potential mechanisms have brought 
diabetes-related scientific research and clinical practice into 
a new era. It could be hypothesized that metabolic memory 
is a newly-formed disease homeostasis that stores past hy-
perglycemic stress in the form of altered macromolecule 
contents (e.g., ROS and AGEs) and epigenetic signatures 
(DNA methylations and histone modifications) and be-
comes a sustained source of cellular hormesis. As a result, it 
may persistently drive the development of diabetic vascu-
lopathies long after the reinstitution of normoglycemia. No-
tably, the hyperglycemic memory of macrovasculature is 
not only a direct result of prior hyperglycemic stimulation, 
but also indirect consequences of secondary biochemical 
and hemodynamic changes. Taken together, more light 
should be shed on metabolic memory-related systemic and 
translational medical researches so as to reduce the inci-
dence of diabetic micro- and macrovasculopathies in the 
coming future. 
850 Zhang EL, et al.   Sci China Life Sci   August (2014) Vol.57 No.8 
This work was supported by the National Natural Science Foundation of 
China (91339103). The authors sincerely thank Teng SiYong, Zhang 
HaiTao, Song GuangYuan, Pei HanJun, Zhao ZhenYan, Wang XiMei, Yao 
Jing, Ding Cheng, He Zhe, Xiao WenQi, Gao HaiYang, Hao Jie, Wu 
DeWei, Guo QianYun, and Wang Yuan for their great assistance during 
manuscript preparation. 
1 Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence 
of diabetes for 2010 and 2030. Diabetes Res Clin Pract, 2010, 87: 
4–14 
2 Banting FG, Best CH. The internal secretion of the pancreas. 1922. 
Indian J Med Res, 2007, 125: 251–266 
3 Nathan DM. The diabetes control and complications tri-
al/epidemiology of diabetes interventions and complications study at 
30 years: Overview. Diabetes Care, 2014, 37: 9–16 
4 The diabetes control and complications trial research group. The ef-
fect of intensive treatment of diabetes on the development and pro-
gression of long-term complications in insulin-dependent diabetes 
mellitus. N Engl J Med, 1993, 329: 977–986 
5 The diabetes control and complications trial/epidemiology of diabetes 
interventions and complications research group. Retinopathy and 
nephropathy in patients with type 1 diabetes four years after a trial of 
intensive therapy. N Engl J Med, 2000, 342: 381–389 
6 Aiello LP. Diabetic retinopathy and other ocular findings in the dia-
betes control and complications trial/epidemiology of diabetes inter-
ventions and complications study. Diabetes Care, 2014, 37: 17–23 
7 de Boer IH. Kidney disease and related findings in the diabetes con-
trol and complications trial/epidemiology of diabetes interventions 
and complications study. Diabetes Care, 2014, 37: 24–30 
8 Martin CL, Albers JW, Pop-Busui R. Neuropathy and related find-
ings in the diabetes control and complications trial/epidemiology of 
diabetes interventions and complications study. Diabetes Care, 2014, 
37: 31–38 
9 Lachin JM, Orchard TJ, Nathan DM. Update on cardiovascular out-
comes at 30 years of the diabetes control and complications tri-
al/epidemiology of diabetes interventions and complications study. 
Diabetes Care, 2014, 37: 39–43 
10 UK prospective diabetes study (UKPDS) group. Intensive 
blood-glucose control with sulphonylureas or insulin compared with 
conventional treatment and risk of complications in patients with type 
2 diabetes (UKPDS 33). Lancet, 1998, 352: 837–853 
11 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year 
follow-up of intensive glucose control in type 2 diabetes. N Engl J 
Med, 2008, 359: 1577–1589 
12 Engerman RL, Kern TS. Progression of incipient diabetic retinopathy 
during good glycemic control. Diabetes, 1987, 36: 808–812 
13 Roy S, Sala R, Cagliero E, Lorenzi M. Overexpression of fibronectin 
induced by diabetes or high glucose: phenomenon with a memory. 
Proc Natl Acad Sci USA, 1990, 87: 404–408 
14 Hammes HP, Klinzing I, Wiegand S, Bretzel RG, Cohen AM, Feder-
lin K. Islet transplantation inhibits diabetic retinopathy in the su-
crose-fed diabetic cohen rat. Invest Ophthalmol Vis Sci, 1993, 34: 
2092–2096 
15 Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, 
Monnier VM. Glycation and carboxymethyllysine levels in skin col-
lagen predict the risk of future 10-year progression of diabetic reti-
nopathy and nephropathy in the diabetes control and complications 
trial and epidemiology of diabetes interventions and complications 
participants with type 1 diabetes. Diabetes, 2005, 54: 3103–3111 
16 Lind M, Oden A, Fahlen M, Eliasson B. The shape of the metabolic 
memory of HbA1c: re-analysing the DCCT with respect to 
time-dependent effects. Diabetologia, 2010, 53: 1093–1098 
17 Miao F, Chen Z, Genuth S, Paterson A, Zhang L, Wu X, Li SM, 
Cleary P, Riggs A, Harlan DM, Lorenzi G, Kolterman O, Sun W, 
Lachin JM, Natarajan R. Evaluating the role of epigenetic histone 
modifications in the metabolic memory of type 1 diabetes. Diabetes, 
2014, 63: 1748–1762 
18 Giacco F, Brownlee M. Oxidative stress and diabetic complications. 
Circ Res, 2010, 107: 1058–1070 
19 Brownlee M. The pathobiology of diabetic complications: a unifying 
mechanism. Diabetes, 2005, 54: 1615–1625 
20 Ihnat MA, Thorpe JE, Kamat CD, Szabo C, Green DE, Warnke LA, 
Lacza Z, Cselenyak A, Ross K, Shakir S, Piconi L, Kaltreider RC, 
Ceriello A. Reactive oxygen species mediate a cellular ‘memory’ of 
high glucose stress signalling. Diabetologia, 2007, 50: 1523–1531 
21 Kowluru RA, Kanwar M, Kennedy A. Metabolic memory phenome-
non and accumulation of peroxynitrite in retinal capillaries. Exp Dia-
betes Res, 2007, 2007: 21976 
22 Santos JM, Kowluru RA. Role of mitochondria biogenesis in the 
metabolic memory associated with the continued progression of dia-
betic retinopathy and its regulation by lipoic acid. Investigative Oph-
thalmol Vis Sci, 2011, 52: 8791–8798 
23 Madsen-Bouterse SA, Mohammad G, Kanwar M, Kowluru RA. Role 
of mitochondrial DNA damage in the development of diabetic reti-
nopathy, and the metabolic memory phenomenon associated with its 
progression. Antioxid Redox Signal, 2010, 13: 797–805 
24 Zhong Q, Kowluru RA. Diabetic retinopathy and damage to mito-
chondrial structure and transport machinery. Invest Ophthalmol Vis 
Sci, 2011, 52: 8739–8746 
25 Santos JM, Kowluru RA. Impaired transport of mitochondrial tran-
scription factor A (TFAM) and the metabolic memory phenomenon 
associated with the progression of diabetic retinopathy. Diabe-
tes/Metab Res Rev, 2013, 29: 204–213 
26 Santos JM, Mishra M, Kowluru RA. Posttranslational modification of 
mitochondrial transcription factor a in impaired mitochondria bio-
genesis: implications in diabetic retinopathy and metabolic memory 
phenomenon. Exp Eye Res, 2014, 121: 168–177 
27 Chan PS, Kanwar M, Kowluru RA. Resistance of retinal inflamma-
tory mediators to suppress after reinstitution of good glycemic con-
trol: novel mechanism for metabolic memory. J Diabetes Compl, 
2010, 24: 55–63 
28 Kowluru RA, Chan PS. Metabolic memory in diabetes—from in vitro 
oddity to in vivo problem: role of apoptosis. Brain Res Bull, 2010, 81: 
297–302 
29 Zheng Z, Chen H, Li J, Li T, Zheng B, Zheng Y, Jin H, He Y, Gu Q, 
Xu X. Sirtuin 1-mediated cellular metabolic memory of high glucose 
via the LKB1/AMPK/ROS pathway and therapeutic effects of met-
formin. Diabetes, 2012, 61: 217–228 
30 Pirola L, Balcerczyk A, Okabe J, El-Osta A. Epigenetic phenomena 
linked to diabetic complications. Nat Rev Endocrinol, 2010, 6: 
665–675 
31 Zhong Q, Kowluru RA. Role of histone acetylation in the develop-
ment of diabetic retinopathy and the metabolic memory phenomenon. 
J Cell Biochem, 2010, 110: 1306–1313 
32 Zhong Q, Kowluru RA. Epigenetic changes in mitochondrial super-
oxide dismutase in the retina and the development of diabetic reti-
nopathy. Diabetes, 2011, 60: 1304–1313 
33 Tewari S, Zhong Q, Santos JM, Kowluru RA. Mitochondria DNA 
replication and DNA methylation in the metabolic memory associat-
ed with continued progression of diabetic retinopathy. Invest Oph-
thalmol Vis Sci, 2012, 53: 4881–4888 
34 Zhong Q, Kowluru RA. Epigenetic modification of SOD2 in the de-
velopment of diabetic retinopathy and in the metabolic memory: role 
of histone methylation. Invest Ophthalmol Vis Sci, 2013, 54: 
244–250 
35 Fang D, Guan H, Liu J, Wei G, Ke W, Yao B, Xiao H, Li Y. Early 
intensive insulin therapy attenuates the p38 pathway in the renal cor-
tex and indices of nephropathy in diabetic rats. Endocr J, 2012, 59: 
81–90 
36 Spanswick DC, Simonds SE, Cowley MA. Transmitter time: synaptic 
plasticity and metabolic memory in the hypothalamus. Cell Metab, 
2012, 15: 275–276 
 Zhang EL, et al.   Sci China Life Sci   August (2014) Vol.57 No.8 851 
37 Kim ES, Isoda F, Kurland I, Mobbs CV. Glucose-induced metabolic 
memory in schwann cells: prevention by ppar agonists. Endocrinolo-
gy, 2013, 154: 3054–3066 
38 Paneni F, Mocharla P, Akhmedov A, Costantino S, Osto E, Volpe M, 
Luscher TF, Cosentino F. Gene silencing of the mitochondrial adap-
tor p66(shc) suppresses vascular hyperglycemic memory in diabetes. 
Circulation research, 2012, 111: 278–289 
39 Corgnali M, Piconi L, Ihnat M, Ceriello A. Evaluation of gliclazide 
ability to attenuate the hyperglycaemic 'memory' induced by high 
glucose in isolated human endothelial cells. Diabetes/Metab Res Rev, 
2008, 24: 301–309 
40 Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker 
EK, Calkin AC, Brownlee M, Cooper ME, El-Osta A. Hyperglyce-
mia induces a dynamic cooperativity of histone methylase and deme-
thylase enzymes associated with gene-activating epigenetic marks 
that coexist on the lysine tail. Diabetes, 2009, 58: 1229–1236 
41 Okabe J, Orlowski C, Balcerczyk A, Tikellis C, Thomas MC, Cooper 
ME, El-Osta A. Distinguishing hyperglycemic changes by Set7 in 
vascular endothelial cells. Circ Res, 2012, 110: 1067–1076 
42 Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, Nata-
rajan R. Epigenetic histone H3 lysine 9 methylation in metabolic 
memory and inflammatory phenotype of vascular smooth muscle 
cells in diabetes. Proc Natl Acad Sci USA, 2008, 105: 9047–9052 
43 Villeneuve LM, Kato M, Reddy MA, Wang M, Lanting L, Natarajan 
R. Enhanced levels of microRNA-125b in vascular smooth muscle 
cells of diabetic db/db mice lead to increased inflammatory gene ex-
pression by targeting the histone methyltransferase Suv39h1. Diabe-
tes, 2010, 59: 2904–2915 
44 Ce GV, Rohde LE, da Silva AM, Punales MK, de Castro AC, Berto-
luci MC. Endothelial dysfunction is related to poor glycemic control 
in adolescents with type 1 diabetes under 5 years of disease: evidence 
of metabolic memory. J Clin Endocrinol Metab, 2011, 96: 1493–1499 
45 Giordano C, Amato MC, Ciresi A, Citarrella R, Mantione L, Acci-
denti M, Panto F, Guarnotta V, Allotta ML, Criscimanna A, Galluzzo 
A. Predictors of microvascular complications in type 1 diabetic pa-
tients at onset: the role of metabolic memory. Eur J Intern Med, 2011, 
22: 266–274 
46 Hirose A, Furushima D, Yamaguchi N, Kitano S, Uchigata Y. Pre-
diction of retinopathy at 20 years after onset in younger-onset type 1 
diabetes using mean metabolic memory-free HbA1c values: the im-
portance of using HbA1c data of total, not partial, diabetes duration. 
Diabetes Care, 2013, 36: 3812–3814 
47 Benitez-Aguirre PZ, Craig ME, Jenkins AJ, Gallego PH, Cusumano J, 
Duffin AC, Hing S, Donaghue KC. Plantar fascia thickness is longi-
tudinally associated with retinopathy and renal dysfunction: a pro-
spective study from adolescence to adulthood. J Diabetes Sci Technol, 
2012, 6: 348–355 
48 Gerrits EG, Lutgers HL, Kleefstra N, Groenier KH, Smit AJ, Gans 
RO, Bilo HJ. Skin advanced glycation end product accumulation is 
poorly reflected by glycemic control in type 2 diabetic patients (zo-
diac-9). J Diabetes Sci Technol, 2008, 2: 572–577 
49 Gradinaru D, Borsa C, Ionescu C, Margina D. Advanced oxidative 
and glycoxidative protein damage markers in the elderly with type 2 
diabetes. J Proteomics, 2013, 92: 313–322 
50 Guay C, Regazzi R. Circulating microRNAs as novel biomarkers for 
diabetes mellitus. Nat Rev Endocrinol, 2013, 9: 513–521 
51 Jansen F, Yang X, Hoelscher M, Cattelan A, Schmitz T, Proebsting S, 
Wenzel D, Vosen S, Franklin BS, Fleischmann BK, Nickenig G, 
Werner N. Endothelial microparticle-mediated transfer of mi-
croRNA-126 promotes vascular endothelial cell repair via SPRED1 
and is abrogated in glucose-damaged endothelial microparticles. Cir-
culation, 2013, 128: 2026–2038 
52 Meng S, Cao JT, Zhang B, Zhou Q, Shen CX, Wang CQ. Downreg-
ulation of microrna-126 in endothelial progenitor cells from diabetes 
patients, impairs their functional properties, via target gene SPRED-1. 
J Mol Cell Cardiol, 2012, 53: 64–72 
53 Putta S, Lanting L, Sun G, Lawson G, Kato M, Natarajan R. Inhibit-
ing microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. 
J Am Soc Nephrol, 2012, 23: 458–469 
54 Kato M, Zhang J, Wang M, Lanting L, Yuan H, Rossi JJ, Natarajan R. 
MicroRNA-192 in diabetic kidney glomeruli and its function in 
TGF-beta-induced collagen expression via inhibition of E-box re-
pressors. Proc Natl Acad Sci USA, 2007, 104: 3432–3437 
55 Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, 
Pogue J, Probstfield J, Ramachandran A, Riddle MC, Ryden LE, 
Yusuf S. Basal insulin and cardiovascular and other outcomes in dys-
glycemia. N Engl J Med, 2012, 367: 319–328 
56 Nichols GA, Joshua-Gotlib S, Parasuraman S. Independent contribu-
tion of A1C, systolic blood pressure, and LDL cholesterol control to 
risk of cardiovascular disease hospitalizations in type 2 diabetes: an 
observational cohort study. J Gen Intern Med, 2013, 28: 691–697 
57 Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. 
Multifactorial intervention and cardiovascular disease in patients with 
type 2 diabetes. N Engl J Med, 2003, 348: 383–393 
58 Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial 
intervention in patients with type 2 diabetes mellitus and microalbu-
minuria: the steno type 2 randomised study. Lancet, 1999, 353: 
617–622 
59 De Boer MP, Meijer RI, Wijnstok NJ, Jonk AM, Houben AJ, 
Stehouwer CD, Smulders YM, Eringa EC, Serne EH. Microvascular 
dysfunction: a potential mechanism in the pathogenesis of obesi-
ty-associated insulin resistance and hypertension. Microcirculation, 
2012, 19: 5–18 
60 Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA. Microcircu-
lation in hypertension: a new target for treatment? Circulation, 2001, 
104: 735–740 
61 Jax TW. Metabolic memory: a vascular perspective. Cardiovasc Dia-
betol, 2010, 9: 51 
 
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction 
in any medium, provided the original author(s) and source are credited. 
